DRREDDY(Dr. Reddy's Laboratories Limited)
31.10.2022 - MS on Drreddy Maintain Overweight CMP 4427.45 Target 5099
31.10.2022 - Nomura on Drreddy Maintain Buy CMp 4427.45 Target 5552
31.10.2022 - Macquarie on Drreddy Maintain CMP 4427.45 Target 4915
16.09.2022 - MS on Drreddy Maintain Overweight CMP 4080 Target 5099
29.07.2022 - MS on Drreddy Maintain Overweight CMP 4091 Target 5099
29.07.2022 - CS on Drreddy Maintain Neutral CMP 4091 Target 4050
29.07.2022 - GS on Drreddy Maintain Neutral CMP 4091 Target 4380
22.06.2022 - Jefferies on Drreddy Maintain Buy CMP 4261 Target 5036
22.06.2022 - CLSA on Drreddy Maintain Buy CMP 4261 Target 4950
22.06.2022 - MS on Drreddy Maintain Overweight CMP 4261 Target 5099
20.05.2022 - CS on Drreddy Maintain Neutral CMP 3929 Target 4465
20.05.2022 - MS on Drreddy Maintain Overweight CMP 3929 Target 5202
08.04.2022 - MS on Drreddy Maintain Overweight CMP 4317.40 Target 5202
07.03.2022 - CLSA on DRREDDY Maintain Buy 3829 Target 5100
02.03.2022 - Nomura on Drreddy Maintain Buy CMP 4063 Target 5552
CLSA ON DR REDDY'S : 15.07.2021
* Dr Reddy's annual report provides a roadmap to scale up key market operations, including stronger US FDA compliance, CLSA says, maintains BUY
* Annual Rpt Gives Roadmap To Scale Up Key Mkt Ops, Incl Stronger US FDA Compliance
* Continued Margin Improvement Should Drive Mid-teens YoY Earnings Growth
* MAINTAIN BUY TARGET: 6,210
MORGAN STANLEY ON DR REDDY'S : 23.06.2021
* Maintain Overweight, Target at Rs 5,859/share
* gVascepa launch a good earnings catalyst
* Expect an earnings up-cycle for DRL, driven by India/EM markets
• Niche US launches & continuing productivity gains expected
* gVascepa is an important US launch playing into this thesis
* gKuvan 500mg powder, gRevlimid, and Sputnik V are other upcoming catalysts
MS ON DR REDDY'S : 23.06.2021
* MS has an Overweight call on Dr Reddy's with an expectation of earnings upcycle, led by India/EM markets
* MAINTAIN OVERWEIGHT TARGET: 5,859
* Expect An Earnings Upcycle, Driven By India/EM Markets
* Niche US Launches & Productivity Gains Will Support Growth
* Vascepa Generic Is An Important US Launch
• Kuvan, Revlimid Generics & Sputnik V Are Other Catalysts
JPMORGAN ON DR REDDY'S : 17.05.2021
* JPMorgan maintains Neutral rating on Dr Reddy's. It says, co has limited near-term triggers
* MAINTAIN NEUTRAL TARGET: 4,850
* Believe Best For The Stock Is Behind Us
* After A Strong Rally Over Apr To Feb, Stock Has Lagged Nifty By 15%
* Core Biz In-line With Historical Average Despite Tractors At Cyclical High
JEFFERIES ON DR REDDY'S : 17.05.2021
* Maintain BUY, Target at Rs 5978/share
* Expects DRL to sell 250mn Sputnik V doses in the next 12 months in India
* Company plans to launch gVasecpa in the next two months with regular supplies
* We change our FY22/23 estimates by -5%/0%
MS ON DR REDDY'S : 17.05.2021
* MS has an Overweight call on Dr Reddy's. Kuvan, Vascepa, Revlimid generic & Sputnik are near-to-mid-term growth drivers
* MAINTAIN OVERWEIGHT TARGET: 5,859
* Seeing Sustained Growth Across Most Of Its Key Markets
* Tight Cost Control & Productivity Gains Are Improving Margin
* Kuvan, Vascepa, Revlimid, Sputnik Are Near-to-mid term Growth Drivers
GOLDMAN SACHS ON DR REDDY'S : 17.05.2021
* Goldman Sachs has a Neutral call on Dr Reddy's with intensity of US mkt pricing pressure & US FDA GMP compliance being key risks
* MAINTAIN NEUTRAL TARGET: 5,250
* Q4 In-line; Focus Is On Sputnik V Ramp-up
* Revise Our FY22-24 EBITDA By Up To 4% On Average
* Litigation Around Key Pipeline Opportunities A Key Risk
* Intensity Of US Mkt Pricing Pressure, US FDA GMP Compliance Key Risks